CG Labz
Peptide Library / Recovery / Healing

Wolverine Blend (BPC-157 + TB-500)

Recovery Blend

Wolverine Blend (BPC-157 + TB-500) Research Protocol

Complete Research Guide 4 min read2 peer-reviewed references

Quickstart Overview

The 'Wolverine' blend combines BPC-157 (a gastric pentadecapeptide that drives local tissue repair) with TB-500 (a Thymosin Beta-4 fragment that promotes systemic cell migration and angiogenesis). The two act on complementary pathways and are the most popular recovery pairing in research.

Reconstitution
Add 2.0 mL bacteriostatic water per 10 mg blend vial
BPC Range
250–500 mcg per administration
TB-500 Range
2–2.5 mg loading
Measuring Reference
Check the vial label for the component ratio
Frequency
Daily (BPC) + 2×/week (TB)
Route (studies)
Subcutaneous

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
BPC-157 + TB-500 (1:1)
Sequence Length
5
CAS
Research compound
Peptide Family
Blend
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.100 mL
Syringe Units
10.0 U
Doses / Vial
20

Units assume a U-100 insulin syringe (100 units = 1 mL). Check the vial label for the BPC:TB ratio; blends complicate exact dose attribution.

Frequency: Daily + 2×/week

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 8-week protocol at approximately 500 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 500 mcg/day × 56 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model combined local + systemic tissue repair.
Schedule
6–12 weeks, loading then maintenance.
Dose Range
BPC 250–500 mcg + TB 2–2.5 mg.

Dosing Protocol

Loading
250–500 mcg BPC + 2–2.5 mg TB, split through the week
Frequency
Daily (BPC) + 2×/week (TB)
Maintenance
Reduce TB frequency after 4–6 weeks
Cycle Length
6–12 weeks
Timing
BPC near injury; TB systemic
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Blends complicate exact per-compound dosing; single-compound controls are cleaner for formal study.
  • Avoid angiogenic compounds in any active-malignancy context.

How This Works

BPC-157 up-regulates growth-factor receptors, activates the FAK-paxillin migration pathway and promotes angiogenesis via VEGFR2, concentrating repair where it is administered. TB-500 sequesters G-actin to accelerate cell migration and down-regulates inflammatory cytokines systemically. Combined, they address local repair and whole-body cell recruitment simultaneously — the rationale for the blend.

Potential Benefits & Side Effects

Reported in research
  • Combined local repair (BPC) and systemic cell migration (TB-500)
  • Angiogenesis and improved microcirculation to injured tissue
  • Reduced inflammation and scar/adhesion formation
  • Faster recovery in tendon, muscle and ligament models
Possible considerations
  • Transient fatigue (TB-500 loading)
  • Head-rush or light-headedness
  • Injection-site irritation
  • Theoretical oncology concern (angiogenic activity)

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] J Physiol Pharmacol
    Sikiric P. et al. BPC 157 in the GI tract and tissue repair.
    View Source
  2. [2] Annals NY Acad Sci
    Goldstein A.L. et al. Thymosin β4 regenerative peptide.
    View Source